Company: MBIO
Filing Date: 2025-04-01
Form Type: 424B3
Source: 0001104659-25-030657
Chunk: 89

Company: MUSTANG BIO, INC.
Filing Date: 2025-04-01
Form: 424B3
Chunk 89
---
 States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors
a better opportunity to create, develop and market competing products.

<div align='center'>46</div>

​

Table of Contents

In addition, patents that may be issued or in-licensed
may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable, or otherwise may not provide any competitive
advantage. Moreover, we may be subject to a third-party pre-issuance submission of prior art to the USPTO, or become involved in opposition,
derivation, reexamination, inter partes review, post-grant review or interference proceedings challenging our patent rights or
the patent rights of others. The costs of these proceedings could be substantial, and it is possible that our efforts to establish priority
of invention would be unsuccessful, resulting in a material adverse effect on our U.S. patent positions. An adverse determination in any
such submission, patent office trial, proceeding or litigation could reduce the scope of, render unenforceable, or invalidate, our patent
rights, allow third parties to commercialize our technologies or products and compete directly with us, without payment to us, or result
in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or
strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with
us to license, develop or commercialize current or future product candidates. Third parties are often responsible for maintaining patent
protection for our product candidates, at our and their expense. If that party fails to appropriately prosecute and maintain patent protection
for a product candidate, our abilities to develop and commercialize products may be adversely affected, and we may not be able to prevent
competitors from making, using and selling competing products. Such a failure to properly protect intellectual property rights relating
to any of our product candidates could have a material adverse effect on our financial condition and results of operations. In addition,
U.S. patent laws may change, which could prevent or limit us from filing patent applications or patent claims to protect products and/or
technologies or limit the exclusivity periods that are available to patent holders, as well as affect the validity, enforceability, or
scope of issued patents.

We and our licensors also rely on trade secrets
and proprietary know-how to protect product candidates. Although we have taken steps to protect our and their